Switch theme
Sign up to access all valuation multiples
Corline Biomedical AB is involved in developing, manufacturing and marketing heparin-based solutions to improve kidney transplantation, cell therapies, and applications in the field of regenerative medicine.
1991
7
LTM Revenue $1.7M
LTM EBITDA -$0.6M
$24.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Corline Biomedical has a last 12-month revenue (LTM) of $1.7M and a last 12-month EBITDA of -$0.6M.
In the most recent fiscal year, Corline Biomedical achieved revenue of $1.0M and an EBITDA of -$2.4M.
Corline Biomedical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Corline Biomedical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.7M | XXX | $1.0M | XXX | XXX | XXX |
| Gross Profit | $1.7M | XXX | $1.4M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 138% | XXX | XXX | XXX |
| EBITDA | -$0.6M | XXX | -$2.4M | XXX | XXX | XXX |
| EBITDA Margin | -36% | XXX | -236% | XXX | XXX | XXX |
| EBIT | -$1.2M | XXX | -$1.4M | XXX | XXX | XXX |
| EBIT Margin | -73% | XXX | -135% | XXX | XXX | XXX |
| Net Profit | -$1.2M | XXX | -$2.4M | XXX | XXX | XXX |
| Net Margin | -73% | XXX | -237% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Corline Biomedical's stock price is SEK 10 (or $1).
Corline Biomedical has current market cap of SEK 245M (or $25.3M), and EV of SEK 233M (or $24.1M).
See Corline Biomedical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $24.1M | $25.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Corline Biomedical has market cap of $25.3M and EV of $24.1M.
Corline Biomedical's trades at 23.9x EV/Revenue multiple, and -10.1x EV/EBITDA.
Equity research analysts estimate Corline Biomedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Corline Biomedical has a P/E ratio of -20.6x.
See valuation multiples for Corline Biomedical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $25.3M | XXX | $25.3M | XXX | XXX | XXX |
| EV (current) | $24.1M | XXX | $24.1M | XXX | XXX | XXX |
| EV/Revenue | 14.4x | XXX | 23.9x | XXX | XXX | XXX |
| EV/EBITDA | -39.8x | XXX | -10.1x | XXX | XXX | XXX |
| EV/EBIT | -19.7x | XXX | -17.7x | XXX | XXX | XXX |
| EV/Gross Profit | 14.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -20.6x | XXX | -10.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -14.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCorline Biomedical's last 12 month revenue growth is 100%
Corline Biomedical's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.
Corline Biomedical's rule of 40 is 93% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Corline Biomedical's rule of X is 213% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Corline Biomedical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 100% | XXX | 108% | XXX | XXX | XXX |
| EBITDA Margin | -36% | XXX | -236% | XXX | XXX | XXX |
| EBITDA Growth | -264% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 93% | XXX | -136% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 213% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 272% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Corline Biomedical acquired XXX companies to date.
Last acquisition by Corline Biomedical was XXXXXXXX, XXXXX XXXXX XXXXXX . Corline Biomedical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Corline Biomedical founded? | Corline Biomedical was founded in 1991. |
| Where is Corline Biomedical headquartered? | Corline Biomedical is headquartered in Sweden. |
| How many employees does Corline Biomedical have? | As of today, Corline Biomedical has 7 employees. |
| Is Corline Biomedical publicy listed? | Yes, Corline Biomedical is a public company listed on STO. |
| What is the stock symbol of Corline Biomedical? | Corline Biomedical trades under CLBIO ticker. |
| When did Corline Biomedical go public? | Corline Biomedical went public in 2015. |
| Who are competitors of Corline Biomedical? | Similar companies to Corline Biomedical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Corline Biomedical? | Corline Biomedical's current market cap is $25.3M |
| What is the current revenue of Corline Biomedical? | Corline Biomedical's last 12 months revenue is $1.7M. |
| What is the current revenue growth of Corline Biomedical? | Corline Biomedical revenue growth (NTM/LTM) is 100%. |
| What is the current EV/Revenue multiple of Corline Biomedical? | Current revenue multiple of Corline Biomedical is 14.4x. |
| Is Corline Biomedical profitable? | Yes, Corline Biomedical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Corline Biomedical? | Corline Biomedical's last 12 months EBITDA is -$0.6M. |
| What is Corline Biomedical's EBITDA margin? | Corline Biomedical's last 12 months EBITDA margin is -36%. |
| What is the current EV/EBITDA multiple of Corline Biomedical? | Current EBITDA multiple of Corline Biomedical is -39.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
